Loading…

Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis

Intracerebral infection of mice with mouse hepatitis virus, a member of the Coronaviridae family, reproducibly results in an acute encephalomyelitis that progresses to a chronic demyelinating disease. The ensuing neuropathology during the chronic stage of disease is primarily immune mediated and sim...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2004-04, Vol.172 (7), p.4018-4025
Main Authors: Glass, William G, Hickey, Michelle J, Hardison, Jenny L, Liu, Michael T, Manning, Jerry E, Lane, Thomas E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23
cites cdi_FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23
container_end_page 4025
container_issue 7
container_start_page 4018
container_title The Journal of immunology (1950)
container_volume 172
creator Glass, William G
Hickey, Michelle J
Hardison, Jenny L
Liu, Michael T
Manning, Jerry E
Lane, Thomas E
description Intracerebral infection of mice with mouse hepatitis virus, a member of the Coronaviridae family, reproducibly results in an acute encephalomyelitis that progresses to a chronic demyelinating disease. The ensuing neuropathology during the chronic stage of disease is primarily immune mediated and similar to that of the human demyelinating disease multiple sclerosis. Secretion of chemokines within the CNS signals the infiltration of leukocytes, which results in destruction of white matter and neurological impairment. The CC chemokine ligand (CCL)5 is localized in white matter tracts undergoing demyelination, suggesting that this chemokine participates in the pathogenesis of disease by attracting inflammatory cells into the CNS. In this study, we administer a mAb directed against CCL5 to mice with established mouse hepatitis virus-induced demyelination and impaired motor skills. Anti-CCL5 treatment decreased T cell accumulation within the CNS based, in part, on viral Ag specificity, indicating the ability to differentially target select populations of T cells. In addition, administration of anti-CCL5 improved neurological function and significantly (p < or = 0.005) reduced the severity of demyelination and macrophage accumulation within the CNS. These results demonstrate that the severity of CNS disease can be reduced through the use of a neutralizing mAb directed against CCL5 in a viral model of demyelination.
doi_str_mv 10.4049/jimmunol.172.7.4018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71767360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18051687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EotvCEyAhn-CUxY43TnKsApRK2yK1havl2JPErWMvscNqX48nw9EughsnS6NvvvHMj9AbStYbsqk_PJpxnJ23a1rm6zLVaPUMrWhRkIxzwp-jFSF5ntGSl2foPIRHQggn-eYlOqMFYYlnK_Tr0kXTen3AD3LqIRrXY9_hOABuGtwMMPon4wBvTS-dxgW-gzDbGLBx-KMZjTNhAI23MD95dYiAr11nbJxkNN4lKPqjC1yqWXwL008_B3x_CBFGvCjvQM8qKW5hnrz1vVFJHEAGWGZI_N0sjTdeg11-dpOmm50FfK8sTD6Y8Aq96KQN8Pr0XqBvnz89NF-y7der6-Zym6kNqWNGa6bLnFFe1FQqKFhXVKzSBLq6lrxljFYkb3Wu26qsclZSzkF1NVSqbiutcnaB3h29u8n_mCFEMZqgwFrpIO0kyuXSjJP_gmlQQXlVJpAdQZUWCRN0YjeZUU4HQYlYMhZ_MhYpY1GKJePU9fakn9sR9N-eU6gJeH8EBtMPezOBCKO0NuFU7Pf7f1S_AS-htQ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18051687</pqid></control><display><type>article</type><title>Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis</title><source>EZB Electronic Journals Library</source><creator>Glass, William G ; Hickey, Michelle J ; Hardison, Jenny L ; Liu, Michael T ; Manning, Jerry E ; Lane, Thomas E</creator><creatorcontrib>Glass, William G ; Hickey, Michelle J ; Hardison, Jenny L ; Liu, Michael T ; Manning, Jerry E ; Lane, Thomas E</creatorcontrib><description>Intracerebral infection of mice with mouse hepatitis virus, a member of the Coronaviridae family, reproducibly results in an acute encephalomyelitis that progresses to a chronic demyelinating disease. The ensuing neuropathology during the chronic stage of disease is primarily immune mediated and similar to that of the human demyelinating disease multiple sclerosis. Secretion of chemokines within the CNS signals the infiltration of leukocytes, which results in destruction of white matter and neurological impairment. The CC chemokine ligand (CCL)5 is localized in white matter tracts undergoing demyelination, suggesting that this chemokine participates in the pathogenesis of disease by attracting inflammatory cells into the CNS. In this study, we administer a mAb directed against CCL5 to mice with established mouse hepatitis virus-induced demyelination and impaired motor skills. Anti-CCL5 treatment decreased T cell accumulation within the CNS based, in part, on viral Ag specificity, indicating the ability to differentially target select populations of T cells. In addition, administration of anti-CCL5 improved neurological function and significantly (p &lt; or = 0.005) reduced the severity of demyelination and macrophage accumulation within the CNS. These results demonstrate that the severity of CNS disease can be reduced through the use of a neutralizing mAb directed against CCL5 in a viral model of demyelination.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.172.7.4018</identifier><identifier>PMID: 15034013</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject>Animals ; Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - therapeutic use ; CCL5 protein ; Cell Migration Inhibition ; Central Nervous System - immunology ; Central Nervous System - pathology ; Central Nervous System - virology ; Chemokine CCL5 - antagonists &amp; inhibitors ; Chemokine CCL5 - biosynthesis ; Chemokine CCL5 - genetics ; Chemokine CCL5 - immunology ; Chemokines, CC - immunology ; Chemokines, CC - metabolism ; Chemotaxis, Leukocyte - immunology ; Coronavirus Infections - immunology ; Coronavirus Infections - pathology ; Coronavirus Infections - therapy ; Demyelinating Diseases - immunology ; Demyelinating Diseases - pathology ; Demyelinating Diseases - prevention &amp; control ; Disease Models, Animal ; Encephalomyelitis - immunology ; Encephalomyelitis - pathology ; Encephalomyelitis - therapy ; Injections, Intraperitoneal ; leukocytes ; Ligands ; Macrophage Activation - immunology ; Macrophages - immunology ; Macrophages - pathology ; Mice ; Mice, Inbred C57BL ; Multiple Sclerosis - immunology ; Multiple Sclerosis - pathology ; Multiple Sclerosis - prevention &amp; control ; Murine hepatitis virus ; Murine hepatitis virus - immunology ; RNA, Messenger - antagonists &amp; inhibitors ; RNA, Messenger - biosynthesis ; Severity of Illness Index ; T-Lymphocyte Subsets - immunology ; T-Lymphocyte Subsets - pathology ; T-Lymphocyte Subsets - virology</subject><ispartof>The Journal of immunology (1950), 2004-04, Vol.172 (7), p.4018-4025</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23</citedby><cites>FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15034013$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glass, William G</creatorcontrib><creatorcontrib>Hickey, Michelle J</creatorcontrib><creatorcontrib>Hardison, Jenny L</creatorcontrib><creatorcontrib>Liu, Michael T</creatorcontrib><creatorcontrib>Manning, Jerry E</creatorcontrib><creatorcontrib>Lane, Thomas E</creatorcontrib><title>Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>Intracerebral infection of mice with mouse hepatitis virus, a member of the Coronaviridae family, reproducibly results in an acute encephalomyelitis that progresses to a chronic demyelinating disease. The ensuing neuropathology during the chronic stage of disease is primarily immune mediated and similar to that of the human demyelinating disease multiple sclerosis. Secretion of chemokines within the CNS signals the infiltration of leukocytes, which results in destruction of white matter and neurological impairment. The CC chemokine ligand (CCL)5 is localized in white matter tracts undergoing demyelination, suggesting that this chemokine participates in the pathogenesis of disease by attracting inflammatory cells into the CNS. In this study, we administer a mAb directed against CCL5 to mice with established mouse hepatitis virus-induced demyelination and impaired motor skills. Anti-CCL5 treatment decreased T cell accumulation within the CNS based, in part, on viral Ag specificity, indicating the ability to differentially target select populations of T cells. In addition, administration of anti-CCL5 improved neurological function and significantly (p &lt; or = 0.005) reduced the severity of demyelination and macrophage accumulation within the CNS. These results demonstrate that the severity of CNS disease can be reduced through the use of a neutralizing mAb directed against CCL5 in a viral model of demyelination.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>CCL5 protein</subject><subject>Cell Migration Inhibition</subject><subject>Central Nervous System - immunology</subject><subject>Central Nervous System - pathology</subject><subject>Central Nervous System - virology</subject><subject>Chemokine CCL5 - antagonists &amp; inhibitors</subject><subject>Chemokine CCL5 - biosynthesis</subject><subject>Chemokine CCL5 - genetics</subject><subject>Chemokine CCL5 - immunology</subject><subject>Chemokines, CC - immunology</subject><subject>Chemokines, CC - metabolism</subject><subject>Chemotaxis, Leukocyte - immunology</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - pathology</subject><subject>Coronavirus Infections - therapy</subject><subject>Demyelinating Diseases - immunology</subject><subject>Demyelinating Diseases - pathology</subject><subject>Demyelinating Diseases - prevention &amp; control</subject><subject>Disease Models, Animal</subject><subject>Encephalomyelitis - immunology</subject><subject>Encephalomyelitis - pathology</subject><subject>Encephalomyelitis - therapy</subject><subject>Injections, Intraperitoneal</subject><subject>leukocytes</subject><subject>Ligands</subject><subject>Macrophage Activation - immunology</subject><subject>Macrophages - immunology</subject><subject>Macrophages - pathology</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple Sclerosis - pathology</subject><subject>Multiple Sclerosis - prevention &amp; control</subject><subject>Murine hepatitis virus</subject><subject>Murine hepatitis virus - immunology</subject><subject>RNA, Messenger - antagonists &amp; inhibitors</subject><subject>RNA, Messenger - biosynthesis</subject><subject>Severity of Illness Index</subject><subject>T-Lymphocyte Subsets - immunology</subject><subject>T-Lymphocyte Subsets - pathology</subject><subject>T-Lymphocyte Subsets - virology</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi0EotvCEyAhn-CUxY43TnKsApRK2yK1havl2JPErWMvscNqX48nw9EughsnS6NvvvHMj9AbStYbsqk_PJpxnJ23a1rm6zLVaPUMrWhRkIxzwp-jFSF5ntGSl2foPIRHQggn-eYlOqMFYYlnK_Tr0kXTen3AD3LqIRrXY9_hOABuGtwMMPon4wBvTS-dxgW-gzDbGLBx-KMZjTNhAI23MD95dYiAr11nbJxkNN4lKPqjC1yqWXwL008_B3x_CBFGvCjvQM8qKW5hnrz1vVFJHEAGWGZI_N0sjTdeg11-dpOmm50FfK8sTD6Y8Aq96KQN8Pr0XqBvnz89NF-y7der6-Zym6kNqWNGa6bLnFFe1FQqKFhXVKzSBLq6lrxljFYkb3Wu26qsclZSzkF1NVSqbiutcnaB3h29u8n_mCFEMZqgwFrpIO0kyuXSjJP_gmlQQXlVJpAdQZUWCRN0YjeZUU4HQYlYMhZ_MhYpY1GKJePU9fakn9sR9N-eU6gJeH8EBtMPezOBCKO0NuFU7Pf7f1S_AS-htQ4</recordid><startdate>20040401</startdate><enddate>20040401</enddate><creator>Glass, William G</creator><creator>Hickey, Michelle J</creator><creator>Hardison, Jenny L</creator><creator>Liu, Michael T</creator><creator>Manning, Jerry E</creator><creator>Lane, Thomas E</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040401</creationdate><title>Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis</title><author>Glass, William G ; Hickey, Michelle J ; Hardison, Jenny L ; Liu, Michael T ; Manning, Jerry E ; Lane, Thomas E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>CCL5 protein</topic><topic>Cell Migration Inhibition</topic><topic>Central Nervous System - immunology</topic><topic>Central Nervous System - pathology</topic><topic>Central Nervous System - virology</topic><topic>Chemokine CCL5 - antagonists &amp; inhibitors</topic><topic>Chemokine CCL5 - biosynthesis</topic><topic>Chemokine CCL5 - genetics</topic><topic>Chemokine CCL5 - immunology</topic><topic>Chemokines, CC - immunology</topic><topic>Chemokines, CC - metabolism</topic><topic>Chemotaxis, Leukocyte - immunology</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - pathology</topic><topic>Coronavirus Infections - therapy</topic><topic>Demyelinating Diseases - immunology</topic><topic>Demyelinating Diseases - pathology</topic><topic>Demyelinating Diseases - prevention &amp; control</topic><topic>Disease Models, Animal</topic><topic>Encephalomyelitis - immunology</topic><topic>Encephalomyelitis - pathology</topic><topic>Encephalomyelitis - therapy</topic><topic>Injections, Intraperitoneal</topic><topic>leukocytes</topic><topic>Ligands</topic><topic>Macrophage Activation - immunology</topic><topic>Macrophages - immunology</topic><topic>Macrophages - pathology</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple Sclerosis - pathology</topic><topic>Multiple Sclerosis - prevention &amp; control</topic><topic>Murine hepatitis virus</topic><topic>Murine hepatitis virus - immunology</topic><topic>RNA, Messenger - antagonists &amp; inhibitors</topic><topic>RNA, Messenger - biosynthesis</topic><topic>Severity of Illness Index</topic><topic>T-Lymphocyte Subsets - immunology</topic><topic>T-Lymphocyte Subsets - pathology</topic><topic>T-Lymphocyte Subsets - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glass, William G</creatorcontrib><creatorcontrib>Hickey, Michelle J</creatorcontrib><creatorcontrib>Hardison, Jenny L</creatorcontrib><creatorcontrib>Liu, Michael T</creatorcontrib><creatorcontrib>Manning, Jerry E</creatorcontrib><creatorcontrib>Lane, Thomas E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glass, William G</au><au>Hickey, Michelle J</au><au>Hardison, Jenny L</au><au>Liu, Michael T</au><au>Manning, Jerry E</au><au>Lane, Thomas E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2004-04-01</date><risdate>2004</risdate><volume>172</volume><issue>7</issue><spage>4018</spage><epage>4025</epage><pages>4018-4025</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>Intracerebral infection of mice with mouse hepatitis virus, a member of the Coronaviridae family, reproducibly results in an acute encephalomyelitis that progresses to a chronic demyelinating disease. The ensuing neuropathology during the chronic stage of disease is primarily immune mediated and similar to that of the human demyelinating disease multiple sclerosis. Secretion of chemokines within the CNS signals the infiltration of leukocytes, which results in destruction of white matter and neurological impairment. The CC chemokine ligand (CCL)5 is localized in white matter tracts undergoing demyelination, suggesting that this chemokine participates in the pathogenesis of disease by attracting inflammatory cells into the CNS. In this study, we administer a mAb directed against CCL5 to mice with established mouse hepatitis virus-induced demyelination and impaired motor skills. Anti-CCL5 treatment decreased T cell accumulation within the CNS based, in part, on viral Ag specificity, indicating the ability to differentially target select populations of T cells. In addition, administration of anti-CCL5 improved neurological function and significantly (p &lt; or = 0.005) reduced the severity of demyelination and macrophage accumulation within the CNS. These results demonstrate that the severity of CNS disease can be reduced through the use of a neutralizing mAb directed against CCL5 in a viral model of demyelination.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>15034013</pmid><doi>10.4049/jimmunol.172.7.4018</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1767
ispartof The Journal of immunology (1950), 2004-04, Vol.172 (7), p.4018-4025
issn 0022-1767
1550-6606
language eng
recordid cdi_proquest_miscellaneous_71767360
source EZB Electronic Journals Library
subjects Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
CCL5 protein
Cell Migration Inhibition
Central Nervous System - immunology
Central Nervous System - pathology
Central Nervous System - virology
Chemokine CCL5 - antagonists & inhibitors
Chemokine CCL5 - biosynthesis
Chemokine CCL5 - genetics
Chemokine CCL5 - immunology
Chemokines, CC - immunology
Chemokines, CC - metabolism
Chemotaxis, Leukocyte - immunology
Coronavirus Infections - immunology
Coronavirus Infections - pathology
Coronavirus Infections - therapy
Demyelinating Diseases - immunology
Demyelinating Diseases - pathology
Demyelinating Diseases - prevention & control
Disease Models, Animal
Encephalomyelitis - immunology
Encephalomyelitis - pathology
Encephalomyelitis - therapy
Injections, Intraperitoneal
leukocytes
Ligands
Macrophage Activation - immunology
Macrophages - immunology
Macrophages - pathology
Mice
Mice, Inbred C57BL
Multiple Sclerosis - immunology
Multiple Sclerosis - pathology
Multiple Sclerosis - prevention & control
Murine hepatitis virus
Murine hepatitis virus - immunology
RNA, Messenger - antagonists & inhibitors
RNA, Messenger - biosynthesis
Severity of Illness Index
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - pathology
T-Lymphocyte Subsets - virology
title Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T17%3A47%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20Targeting%20of%20the%20CC%20Chemokine%20Ligand%205%20Results%20in%20Diminished%20Leukocyte%20Infiltration%20into%20the%20Central%20Nervous%20System%20and%20Reduced%20Neurologic%20Disease%20in%20a%20Viral%20Model%20of%20Multiple%20Sclerosis&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Glass,%20William%20G&rft.date=2004-04-01&rft.volume=172&rft.issue=7&rft.spage=4018&rft.epage=4025&rft.pages=4018-4025&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.172.7.4018&rft_dat=%3Cproquest_cross%3E18051687%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-193d72316591ace53f5838d0ef99a6b331802bd2db878237166ecf9e8c9b8dc23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18051687&rft_id=info:pmid/15034013&rfr_iscdi=true